Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

inical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    [1] Robison CD et al, 2009; Mojana J et al, 2008; Krebs I et al, 2007
    For further information please contact:

    ThromboGenics

    Dr. Patrik De Haes, CEO                   Tel: + 32-16-75-13-1
                                              '/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  Makindus, Inc. a ... that the European Medicines Agency (EMA) has granted orphan ... treatment of Stargardt,s Disease. "We are extremely ... to treat Stargardt,s disease in place for ... program in the United States ...
(Date:5/4/2015)... -- By looking at the brain, scientists believe it ... different conditions that can have very similar symptoms. ... a Denver -based psychiatrist specializing ... can help the medical community better identify the ... Stress Disorder (PTSD) and Traumatic Brain Injury (TBI). ...
(Date:5/4/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) has entered ... to develop and commercialize ISIS-FXI Rx for the ... Isis is eligible to receive up to $155 million ... payment and a $55 million payment upon advancement of ... with compromised kidney function. Isis is also eligible to ...
Breaking Medicine Technology:European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
... Equity Fund (EEF), a healthcare-focused private equity firm, and ... Inc. (MedTest), a medical diagnostic company based in Cortlandt ... diagnostics business from Polymedco, Inc.  The transaction was led ... not disclosed. "EEF is committed to building ...
... / PRNewswire / -- Silicon Valley ... life science companies worldwide, released a study ... private, venture capital-backed biotech and medical device companies. ... acquisition transactions of US venture-capital backed companies (60 biotech ...
Cached Medicine Technology:Enhanced Equity Fund and James White Invest in MedTest DX, Inc. 2Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 2Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 3
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 Lauren ... goods retailer City Sports , was named one ... and active lifestyle industry by the SportsOneSource ... , Ms. Blanda, 33, is one of 40 executives ... Sporting Goods Business magazine) recognized for exceptional achievement in ...
(Date:5/4/2015)... Parlin, New Jersey (PRWEB) May 04, 2015 ... contest to give a chance to more youths to participate ... to encourage youths in her area to do good deeds ... behavior, Dr.Blagoev intends to empower their minds and teach them ... The contest is accessible to any youth 18 years of ...
(Date:5/4/2015)... NY (PRWEB) May 05, 2015 ... honors Irene Taylor , Volunteer Executive ... as a 2015-2016 inductee into its VIP Woman ... this prestigious distinction for leadership in business. NAPW ... professional women, boasting more than 700,000 members and ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Patti Hommes as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... 05, 2015 The National Association ... Betancourt as a 2015-2016 inductee into the NAPW ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor," said NAPW President Star Jones. ...
Breaking Medicine News(10 mins):Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 3Health News:10 More Days To Enter Good Deed Contest 2Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2
... N.C., Nov. 24 In January, victorious,politicians will go ... and health care, but patients don,t have to wait ... care. Instead, they should give,feedback directly to their doctors, ... "We don,t know whether ...
... LOS ANGELES, Nov. 24 To everyone around her, ... acting career, a successful clothing,line that was attracting international ... that for years, Melissa suffered from severe,breathing problems, extreme ... cause. , After ...
... easier, Fresho.com becomes a job search engine with the functionality of a ... ... Due to the current economic woes, employment sites are experiencing an increase ... increasing demand for new job openings, Fresho has changed its business concept ...
... A new study found that adolescents were at the greatest ... early age and the parents, smoking quickly reached high levels ... the November issue of Health Psychology , draws from ... research that suggests smoking behavior is influenced by both genetics ...
... ultrasound waves for deep vein thrombosis (DVT) may help dissolve ... according to researchers at Emory University. The study will be ... New York City. , "These clots are a main cause ... you can eliminate them the better," says Karthikeshwar Kasirajan, MD, ...
... its kind, researchers at the Yerkes National Primate ... have developed a multidisciplinary approach involving immunology, genomics ... vaccine without exposing individuals to infection. This approach ... vaccines--that of only being able to determine immunity ...
Cached Medicine News:Health News:Politicians May Not Listen ... But Doctors Do, Says DrScore 2Health News:Do You Have Genetic COPD? 2Health News:Fresho.com Adapts As The Online Recruiting Market Heats Up 2Health News:Smoking, teens and their parents: New research 2Health News:Ultrasound waves aid in rapid treatment of DVT 2Health News:Researchers discover strategy for predicting the immunity of vaccines 2
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
... Hydroxyprogesterone (17aOHP) is produced by both ... 17aOHP has relatively little progestational activity, ... because it is the,immediate precursor to ... by 21-hydroxylation of 17aOHP,measurement of 17aOHP ...
Medicine Products: